CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

Novo Nordisk (NVO) announced on Saturday that a late-stage trial for its popular weight loss therapy Ozempic in adults with ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...

Among patients with diabetes and peripheral artery disease, semaglutide 1 mg increased walking distance vs. placebo, ...

Semaglutide, the diabetes and weight loss drug that’s commonly known as Ozempic, can help patients of peripheral artery ...

Researchers report yet another positive finding for GLP-1s. The participants in this trial had lower BMIs than the participants in the many other trials that have shown the benefits of the GLP-1s.

COLUMBIA SC (WOLO) – We all understand the importance of the heart, but there are some other afflictions related to the ...

A scientific statement regarding sex differences in patients with peripheral vascular disease has been published by the AHA.

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery ...

A large clinical trial, co-led by researchers at the UNC School of Medicine, has shown that the popular weight-loss drug ...

The following is a summary of the "Patients Undergoing Major Amputation for Peripheral Arterial Disease Are at High Risk for ...